Evidence map›Paper›PMID 34950454›Full record

ArticleF1000Research2021

Cost-effectiveness of hydroxychloroquine

Sarah J Ronaldson, Ada Keding, Puvan Tharmanathan, Catherine Arundel, Sarah R Kingsbury, Philip G Conaghan, David J Torgerson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Sarah J RonaldsonYork Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.ORCID 0000-0001-8321-786X
Ada KedingYork Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.
Puvan TharmanathanYork Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.
Catherine ArundelYork Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.ORCID 0000-0003-0512-4339
Sarah R KingsburyLeeds Institute of Rheumatic and Musculoskeletal Medicine, and NIHR Leeds Biomedical Research Centre, University of Leeds, Leeds, LS7 4SA, UK.
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, and NIHR Leeds Biomedical Research Centre, University of Leeds, Leeds, LS7 4SA, UK.
David J TorgersonYork Trials Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.ORCID 0000-0002-1667-4275
University of York · GBUniversity of Leeds · GB

Funding

Department of HealthVersus Arthritis 19545
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HydroxychloroquineOsteoarthritisAdultCost-Benefit AnalysisHumansQuality of LifeState MedicineHydroxychloroquinecost-effectiveness analysiscost-utility analysiseconomic evaluationhand osteoarthritishydroxychloroquinerandomised controlled trial

Identifiers

PMID34950454
PMCPMC8666991
OpenAlexW3195010929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.